Table 1.
Tanabe’s research [9] | |||||
Group |
Mean dose before reduction |
Reduction speed |
GAF |
SOI |
n |
Successful |
1,372 mg CP |
40.4 mg CP/week |
34.1 |
4.5 |
37 |
Unsuccessful |
1,832 mg CP |
95.4 mg CP/week |
29.8 |
4.8 |
11 |
Murasugi’s research [10] | |||||
Group |
Mean dose before reduction |
Reduction speed |
GAF |
SOI |
n |
Successful |
1,581 mg CP |
43.0 mg CP/week |
35.2 |
4.8 |
5 |
Unsuccessful |
2,389 mg CP |
97.4 mg CP/week |
44.0 |
4.5 |
5 |
Combination of both studies | |||||
Group |
Mean dose before reduction |
Reduction speed |
GAF |
SOI |
n |
Successful |
1,397 mg CP |
40.7 mg/week |
33.5 |
4.5 |
42 |
Unsuccessful | 2, 006 mgCP | 96.0 mg/week | 34.2 | 4.7 | 16 |
Abbreviations: GAF global assessment of functioning in DSM-4-TR; SOI severity of illness; n number of patients.